pio3 / Shutterstock.com (Warner-Lambert, now a part of Pfizer, pictured)
After the English High Court yesterday heard the second day’s arguments in the dispute between Actavis and Warner-Lambert concerning second medical use patents, two lawyers have told LSIPR that similar cases may be on the horizon.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Lyrica, second medical use patent, patent infringement, Actavis, Pfizer
